Tom Riga named President and Chief Executive Officer and will join the Board of Directors effective December 31, 2021 Joe Turgeon , President and Chief Executive Officer, to retire and step down from Board of Directors HENDERSON, Nev. --(BUSINESS WIRE)--Dec. 1, 2021-- Spectrum Pharmaceuticals, Inc.

HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 30, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the JMP Securities Hematology and Oncology Summit, a virtual presentation

HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 11, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the 2021 Jefferies London Healthcare Conference .

Poziotinib NDA is on track for submission in 2021 under a Fast Track designation Positive front line poziotinib data presented at ESMO Congress 2021 from Cohort 4 of the ZENITH20 clinical trial Preclinical data presented at 2021 AACR-NCI-EORTC (Triple) conference demonstrated the synergistic impact

HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 3, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the third quarter 2021 financial results and provide a corporate

HENDERSON, Nev. --(BUSINESS WIRE)--Oct. 7, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the presentation of preclinical data demonstrating the synergistic impact of poziotinib when combined with KRAS

HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 22, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the 2021 Cantor Virtual Global Healthcare Conference .

Early data from Cohort 4 of the ongoing ZENITH20 clinical trial shows ORR of 44% in 48 first-line patients treated with 16mg of poziotinib once daily HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 18, 2021-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and

HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 13, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a late-breaking presentation of early poziotinib efficacy and safety data in first-line patients with non-small

Submission of poziotinib NDA on track for later in 2021 under a Fast Track designation The company is requesting a meeting with the FDA to clarify the remediation timelines regarding the Complete Response Letter (CRL) for ROLONTIS ® (eflapegrastim) Management to host webcast and conference call

HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 6, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the

HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 5, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the second quarter 2021 financial results and provide a corporate

HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 4, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today presented an e-poster on poziotinib CNS activity in patients with NSCLC with EGFR or HER2 exon 20 mutations.

HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 1, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) is “on site” for the ROLONTIS® (eflapegrastim) manufacturing

HENDERSON, Nev. --(BUSINESS WIRE)--May 28, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation on poziotinib CNS activity in patients with NSCLC with EGFR or HER2 exon 20 mutations.

HENDERSON, Nev. --(BUSINESS WIRE)--May 27, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at

Poziotinib NDA on track for 2021 submission New poziotinib twice daily dosing (BID) data presented at AACR demonstrated improved anti-tumor activity and better tolerance FDA pre-approval inspection at the ROLONTIS ® manufacturing facility scheduled for May 2021 Management to host webcast and

HENDERSON, Nev. --(BUSINESS WIRE)--May 6, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the first quarter 2021 financial results and provide a corporate update

HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 10, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today presented a data update on the safety and tolerability of twice daily (BID) administered poziotinib in NSCLC patients

HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 5, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation on safety and tolerability of twice daily administered poziotinib in patients with EGFR or